Clinical Trial Update: Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sorafenib with or without doxorubicin in advanced or recurrent hepatocellular carcinoma has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2018-05-02